SCHEMBL338541

SCHEMBL338541

CCC(=O)Nc1c(-c2ccccc2)cccc1C(C)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
GAA P10253 1/20 0.43
SOAT1 P35610 4/20 0.43
SOAT2 O75908 2/20 0.43
CXCL8 P10145 1/20 0.43
ADORA3 P0DMS8 3/20 0.42
ADORA2A P29274 3/20 0.42
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ADORA2B P29275 2/20 0.42
ADORA1 P30542 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
NPC1 O15118 1/20 0.42
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL341491 0.90 SOAT1 (0.46) MAPTSOAT1SOAT2CXCL8ADORA3
SCHEMBL340819 0.86 MAPT (0.39) MAPTGAASOAT1SOAT2CXCL8
SCHEMBL339362 0.85 CXCL8 (0.46) MAPTCXCL8ADORA3ALDH1A1SMN1; SMN2
SCHEMBL341017 0.83 KMT2A (0.45) MAPTCXCL8ADORA3ADORA2AALDH1A1
SCHEMBL3125901 0.78 PTGS1 (0.45) MAPTGAACXCL8ADORA3SMN1; SMN2
SCHEMBL368609 0.78 PTGS2 (0.43) SOAT1PTGS2
SCHEMBL2965336 0.77 HNF4A (0.50) MAPTGAASOAT1ADORA3ADORA2A
SCHEMBL341352 0.77 LMNA (0.50) MAPTCXCL8ADORA3ADORA2AALDH1A1
SCHEMBL18061111 0.76 TAAR1 (0.51) ALDH1A1SMN1; SMN2MEN1KMT2APOLB
SCHEMBL2393839 0.76 PTGS2 (0.56) MAPTCXCL8SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181175-B2 Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) 2015-11-10 US disclosed
EP-2387558-B1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARM CO LTD (CN) 2014-08-27 EP disclosed
US-20140179947-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2014-06-26 US disclosed
US-8703990-B2 Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) 2014-04-22 US disclosed
US-20120016151-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID NOVARTIS AG (CH) 2012-01-19 US disclosed
EP-2387558-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) 2011-11-23 EP disclosed
US-20110253230-A1 Temperature Sensitive Valve Having Shape Memory Actuator OMNITEK PARTNERS LLC (US) 2011-10-20 US disclosed
WO-2010081410-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2010-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179947-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID DNPEP, MME, DPP7 MAPT 1676/4885GAA 37/4885SOAT1 1675/4885
US-20120016151-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID DNPEP, MME, DPP7 MAPT 1676/4885GAA 37/4885SOAT1 1675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.